Your browser doesn't support javascript.
Serial Thromboelastography and the Development of Venous Thromboembolism in Critically Ill Patients With COVID-19.
Marvi, Tanya K; Stubblefield, William B; Tillman, Benjamin F; Tenforde, Mark W; Patel, Manish M; Lindsell, Christopher J; Self, Wesley H; Grijalva, Carlos G; Rice, Todd W.
  • Marvi TK; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
  • Stubblefield WB; Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN.
  • Tillman BF; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
  • Tenforde MW; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA.
  • Patel MM; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA.
  • Lindsell CJ; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN.
  • Self WH; Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN.
  • Grijalva CG; Vanderbilt Institute for Clinical and Translational Research (VICTR), Vanderbilt University Medical Center, Nashville, TN.
  • Rice TW; Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN.
Crit Care Explor ; 4(1): e0618, 2022 Jan.
Article in English | MEDLINE | ID: covidwho-1635227
ABSTRACT
To test the hypothesis that relatively lower clot strength on thromboelastography maximum amplitude (MA) is associated with development of venous thromboembolism (VTE) in critically ill patients with COVID-19.

DESIGN:

Prospective, observational cohort study.

SETTING:

Tertiary care, academic medical center in Nashville, TN. PATIENTS Patients with acute respiratory failure from COVID-19 pneumonia admitted to the adult medical ICU without known VTE at enrollment.

INTERVENTIONS:

None. MEASUREMENTS AND MAIN

RESULTS:

Ninety-eight consecutive critically ill adults with laboratory-confirmed COVID-19 were enrolled. Thromboelastography parameters and conventional coagulation parameters were measured on days 0 (within 48 hr of ICU admission), 3, 5, and 7 after enrollment. The primary outcome was diagnosis of VTE with confirmed deep venous thrombosis and/or pulmonary embolism by clinical imaging or autopsy. Twenty-six patients developed a VTE. Multivariable regression controlling for antiplatelet exposure and anticoagulation dose with death as a competing risk found that lower MA was associated with increased risk of VTE. Each 1 mm increase in enrollment and peak MA was associated with an 8% and 14% decrease in the risk of VTE, respectively (enrollment MA subdistribution hazard ratio [SHR], 0.92; 95% CI, 0.87-0.97; p = 0.003 and peak MA SHR, 0.86; 95% CI, 0.81-0.91; p < 0.001). Lower enrollment platelet counts and fibrinogen levels were also associated with increased risk of VTE (p = 0.002 and p = 0.01, respectively). Platelet count and fibrinogen level were positively associated with MA (multivariable model adjusted R 2 = 0.51; p < 0.001).

CONCLUSIONS:

When controlling for the competing risk of death, lower enrollment and peak MA were associated with increased risk of VTE. Lower platelet counts and fibrinogen levels at enrollment were associated with increased risk of VTE. The association of diminished MA, platelet counts, and fibrinogen with VTE may suggest a relative consumptive coagulopathy in critically ill patients with COVID-19.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: Crit Care Explor Year: 2022 Document Type: Article Affiliation country: CCE.0000000000000618

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: Crit Care Explor Year: 2022 Document Type: Article Affiliation country: CCE.0000000000000618